Valneva (NASDAQ:VALN - Get Free Report) had its target price reduced by stock analysts at HC Wainwright from $18.00 to $17.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's price objective would indicate a potential upside of 128.49% from the company's previous close. HC Wainwright also issued estimates for Valneva's Q4 2024 earnings at ($0.17) EPS, Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.36) EPS, FY2026 earnings at ($1.23) EPS and FY2027 earnings at ($1.28) EPS.
Valneva Stock Performance
Shares of VALN traded down $0.47 during mid-day trading on Wednesday, hitting $7.44. The stock had a trading volume of 51,800 shares, compared to its average volume of 67,211. The firm has a market cap of $604.57 million, a P/E ratio of -57.23 and a beta of 1.98. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The business has a fifty day moving average price of $5.18 and a 200-day moving average price of $5.67. Valneva has a 52 week low of $3.62 and a 52 week high of $9.50.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of VALN. Wells Fargo & Company MN increased its position in Valneva by 14.3% during the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock valued at $1,079,000 after buying an additional 30,859 shares in the last quarter. AlphaCentric Advisors LLC boosted its position in shares of Valneva by 33.7% during the third quarter. AlphaCentric Advisors LLC now owns 118,000 shares of the company's stock valued at $717,000 after buying an additional 29,748 shares during the period. Finally, ABC Arbitrage SA purchased a new stake in shares of Valneva in the fourth quarter valued at approximately $84,000. Institutional investors own 11.39% of the company's stock.
About Valneva
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Further Reading
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
